Revenue: As of FY2025 Q2, the actual value is USD 0.EPS: As of FY2025 Q2, the actual value is USD 0.EBIT: As of FY2025 Q2, the actual value is USD -1.08 M.<h3>Segment Revenue</h3><ul><li>The company did not generate revenue during the three months ended June 30, 2025 and 2024.</li></ul><h3>Operational Metrics</h3><ul><li>Net Income (Loss): For the three months ended June 30, 2025, net income was $113,287 compared to a net loss of $961,207 for the same period in 2024.</li><li>Loss from Operations: Loss from operations was - $1,118,211 for the three months ended June 30, 2025, compared to - $909,218 for the same period in 2024.</li><li>Total Operating Expenses: Total operating expenses were $1,118,211 for the three months ended June 30, 2025, compared to $909,218 for the same period in 2024.</li></ul><h3>Cash Flow</h3><ul><li>Net Cash Used in Operating Activities: - $8,975,859 for the six months ended June 30, 2025, compared to - $1,104,287 for the same period in 2024.</li><li>Net Cash Used in Investing Activities: - $775,000 for the six months ended June 30, 2025, compared to - $1,500,000 for the same period in 2024.</li><li>Net Cash Provided by Financing Activities: $11,032,762 for the six months ended June 30, 2025, compared to $2,204,000 for the same period in 2024.</li></ul><h3>Unique Metrics</h3><ul><li>Forgiveness of Unrelated Vendor Payables: The company recognized a gain of $2,142,297 related to the settlement of TDT’s payables during the three months ended June 30, 2025.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to raise additional cash through equity and debt financings or other arrangements to fund operations. There is substantial doubt about its ability to continue as a going concern within one year after the date that the accompanying unaudited condensed consolidated financial statements are issued.</li><li>Non-Core Business: The company has terminated its license agreements with TDT as of August 11, 2024, and entered into a settlement agreement on June 16, 2025, releasing it from all amounts due to TDT.</li></ul>

LIMINATUS PHARMA INC C/WTS 30/04/2030 (TO PUR COM) | 10-Q: FY2025 Q2 Revenue: USD 0